SLC7A8 coding for LAT2 is associated with early disease progression in osteosarcoma and transports doxorubicin

Background: Despite (neo) adjuvant chemotherapy with cisplatin, doxorubicin and methotrexate, some patients with primary osteosarcoma progress during first-line systemic treatment and have a poor prognosis. In this study, we investigated whether patients with early disease progression (EDP), are cha...

Descripción completa

Detalles Bibliográficos
Autores principales: Hurkmans, Evelien G. E., Koenderink, Jan B., van den Heuvel, Jeroen J. M. W., Versleijen-Jonkers, Yvonne M. H., Hillebrandt-Roeffen, Melissa H. S., Groothuismink, Johanne M., Vos, Hanneke I., van der Graaf, Winette T. A., Flucke, Uta, Muradjan, Grigor, Schreuder, Hendrik W. B., Hagleitner, Melanie M., Brunner, Han G., Gelderblom, Hans, Cleton-Jansen, Anne-Marie, Guchelaar, Henk-Jan, de Bont, Eveline S. J. M., Touw, Daan J., Nijhoff, G. Jan, Kremer, Leontien C. M., Caron, Huib, Windsor, Rachael, Patiño-García, Ana, González-Neira, Anna, Saletta, Federica, McCowage, Geoff, Nagabushan, Sumanth, Catchpoole, Daniel, te Loo, D. Maroeska W. M., Coenen, Marieke J. H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9681801/
https://www.ncbi.nlm.nih.gov/pubmed/36438828
http://dx.doi.org/10.3389/fphar.2022.1042989

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9681801/
https://www.ncbi.nlm.nih.gov/pubmed/36438828
http://dx.doi.org/10.3389/fphar.2022.1042989

Ejemplares similares